Increased incidence of chronic GvHD and CMV disease in patients with Vitamin D deficiency before allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 50, Issue 9, 2015, Pages 1217-1223

  Von Bahr, L ^a,b   Blennow, O ^b   Alm, J ^b   Bjorklund A ^a,b   Malmberg, K J ^a,b,c,d   Mougiakakos, D ^e   Le Blanc, A ^a   Oefner, P J ^f   Labopin, M ^g   Ljungman, P ^a   Le Blanc, K ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VITAMIN D;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOLOGICAL TOLERANCE; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOMA; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SURVIVAL RATE; VIRUS LOAD; VITAMIN D DEFICIENCY; ALLOGRAFT; CHRONIC DISEASE; COMPLICATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; NEOPLASMS;

ADULT; ALLOGRAFTS; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; VITAMIN D DEFICIENCY;

EID: 84940894814     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.123     Document Type: Article

References (38)

1. Maruotti N, Cantatore FP. Vitamin D and the immune system. J Rheumatol 2010; 37: 491-495.
2. Chun RF, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin D on immune function: lessons learned from genome-wide analysis. Front Physiol 2014; 5: 151.
3. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008; 8: 685-698.
4. Chu C-C, Ali N, Karagiannis P, Di Meglio P, Skowera A, Napolitano L et al. Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med 2012; 209: 935-945.
5. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-2411.
6. Glotzbecker B, Ho VT, Aldridge J, Kim HT, Horowitz G, Ritz J et al. Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. Bone Marrow Transplant 2012; 48: 593-597.
7. Benrashid M, Moyers K, Mohty M, Savani BN. Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: Implication for preventive therapy. Exp Hematol 2012; 40: 263-267.
8. Rosenblatt J, Bissonnette A, Ahmad R, Wu Z, Vasir B, Stevenson K et al. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant 2010; 45: 1463-1468.
9. Park M-J, Min S-Y, Park K-S, Cho Y-G, Cho M-L, Jung Y-O et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collageninduced arthritis mouse model. Arthritis Res Ther 2008; 10: R11.
10. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005; 19: 1067-1077.
11. Wang T-T, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-2912.
12. Wilson SS, Wiens ME, Smith JG. Antiviral mechanisms of human defensins. J Mol Biol 2013; 425: 4965-4980.
13. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012; 280: 22-35.
14. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
15. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
16. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
17. Pérez-Bercoff L, Vudattu NK, Byrareddy SN, Mattsson J, Maeurer M, Ljungman P. Reduced IL-7 responsiveness defined by signal transducer and activator of transcription phosphorylation in T cells may be a marker for increased risk of developing cytomegalovirus disease in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 128-132.
18. Forslöw U, Blennow O, LeBlanc K, Ringdén O, Gustafsson B, Mattsson J et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2012; 89: 220-227.
19. Pedersen JI. Vitamin D requirement and setting recommendation levels-current Nordic view. Nutr Rev 2008; 66: S165-S169.
20. Zhu W, Stevens AP, Dettmer K, Gottfried E, Hoves S, Kreutz M et al. Quantitative profiling of tryptophan metabolites in serum, urine, and cell culture supernatants by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011; 401: 3249-3261.
21. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351: 805-806.
22. Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn B-M, Mattsson J et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant 2013; 48: 537-543.
23. Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
24. Vieth R. The Pharmacology of Vitamin D. Feldman D, Pike JW, Adams JS (eds) Vitamin D. 3rd edn Academic: New York: NY, 2011; 1041-1066.
25. Landfried K, Zhu W, Waldhier MC, Schulz U, Ammer J, Holler B et al. Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood 2011; 118: 6971-6974.
26. Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B et al. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2013; 27: 377-388.
27. Silva F, Pérez-Simón JA, Caballero-Velazquez T, Sánchez-Guijo FM, Villanueva-Gomez F, Vazquez L et al. Effect of vitamin D treatment in chronic GVHD. Bone Marrow Transplant 2011; 46: 1395-1397.
28. Hansson MEA, Norlin A-C, Omazic B, Wikström A-C, Bergman P, Winiarski J et al. Vitamin D levels affect outcome in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1537-1543.
29. Sproat L, Bolwell B, Rybicki L, Dean R, Sobecks R, Pohlman B et al. Vitamin D level after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2011; 17: 1079-1083.
30. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C et al. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 2011; 86: 954-956.
31. Cavalier M, Shmalo JA, Yu M, Billings SD, Abonour R, Nelson RP Jr. Skin cancer after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant 2006; 37: 1103-1108.
32. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930.
33. Kragt J, van Amerongen B, Killestein J, Dijkstra C, Uitdehaag B, Polman C et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009; 15: 9-15.
34. Littorin B, Blom P, Schölin A, Arnqvist HJ, Blohmé G, Bolinder J et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 2006; 49: 2847-2852.
35. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004; 50: 72-77.
36. Bitetto D, Fabris C, Falleti E, Fornasiere E, Fumolo E, Fontanini E et al. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int 2010; 30: 417-444.
37. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500-1503.
38. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch H-M, Cheung R et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852-1859.